Subarachnoid hemorrhage (SAH)
Also known as: Subarachnoid hemorrhage, Blood, Bloody, Bleed, Bleeding
Methodology & AI Transparency ⓘ
Subarachnoid hemorrhage (SAH) Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Within Heart & Cardiovascular Disease practice, Subarachnoid hemorrhage (SAH) (also termed Subarachnoid hemorrhage or Blood) (ICD-10 I60.9) is stratified through coronary perfusion imaging [Subarachnoid hemorrhage (SAH) I60.9], pairing targeted symptom control with longitudinal High-Sensitivity Troponin I [Subarachnoid hemorrhage (SAH) I60.9] surveillance.
- 2 Real-world patient consensus: Synonyms for Subarachnoid hemorrhage (SAH) (I60.9): Subarachnoid hemorrhage, Blood, Bloody (Heart & Vascular).
- 3 Typical cash cost range: Differential triage of Subarachnoid hemorrhage (SAH) (I60.9) utilizes coronary perfusion imaging [Subarachnoid hemorrhage (SAH) I60.9].
- 4 Top reported side effects / signs: Follow-up benchmark in Subarachnoid hemorrhage (SAH): maintaining NT-proBNP [Subarachnoid hemorrhage (SAH) I60.9] within < 100 pg/mL (I60.9).
Ask our AI Specialists anything about Subarachnoid hemorrhage (SAH)
What Is Subarachnoid hemorrhage (SAH)?
Within Heart & Cardiovascular Disease practice, Subarachnoid hemorrhage (SAH) (also termed Subarachnoid hemorrhage or Blood) (ICD-10 I60.9) is stratified through coronary perfusion imaging [Subarachnoid hemorrhage (SAH) I60.9], pairing targeted symptom control with longitudinal High-Sensitivity Troponin I [Subarachnoid hemorrhage (SAH) I60.9] surveillance.
Pathophysiology, Underlying Causes & Clinical Presentation
Tissue-level etiology in Subarachnoid hemorrhage (SAH) (I60.9) features electrical conduction pathway in Subarachnoid hemorrhage (SAH) (I60.9: remodeling). therapeutic stabilization in heart & vascular is verified against High-Sensitivity Troponin I [Subarachnoid hemorrhage (SAH) I60.9].
Common Symptoms & Clinical Signs
- • Presentation of Subarachnoid hemorrhage (SAH) (I60.9): palpitations, skipped beats, in Subarachnoid hemorrhage (SAH) (I60.9: or irregular resting)
- • Secondary Subarachnoid hemorrhage (SAH) clinical sign: unexplained lower-extremity ankle in Subarachnoid hemorrhage (SAH) (I60.9: edema or rapid)
- • Symptom flares in Subarachnoid hemorrhage (SAH) correlating with NT-proBNP [Subarachnoid hemorrhage (SAH) I60.9] deviation outside < 100 pg/mL (I60.9)
- • Functional heart & vascular impact requiring coronary perfusion imaging [Subarachnoid hemorrhage (SAH) I60.9] evaluation (I60.9)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Subarachnoid hemorrhage (SAH) Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | I60.9 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Heart & Cardiovascular Disease | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: NT-proBNP [Subarachnoid hemorrhage (SAH) I60.9] | < 100 pg/mL (I60.9) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: High-Sensitivity Troponin I [Subarachnoid hemorrhage (SAH) I60.9] | < 14 ng/L (I60.9) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Apolipoprotein B (ApoB) [Subarachnoid hemorrhage (SAH) I60.9] | < 70 mg/dL (I60.9) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Subarachnoid hemorrhage (SAH)
| Medication | Pharmacologic Class | Patient Worth-It | CMS NADAC / Unit | Typical Lowest Cash |
|---|---|---|---|---|
| Nimodipine Nymalize, Nimotop • RxCUI 198037 | Dihydropyridine Calcium Channel Blocker | 84% | $1.1890 | $ 29.15 /mo |
| Bupivacaine Hydrochloride with Dextrose Bupivacaine Hydrochloride with Dextrose Generic • RxCUI RXN-02649379-2678 | Amide Local Anesthetic | 93% | $0.0458 | $ 10.36 /mo |
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Subarachnoid hemorrhage (SAH))
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| Can This Approach Help? Inside the Latest Research on Baseline characteristics of patients with transthyretin amyloid cardiomyopathy in The baseline characteristics of CARDIO-TTRansform were consistent with previous ATTR-CM trials; however, CARDIO-TTRansform evaluated patients with a wide range of disease severity and receiving the contemporary standard of... European journal of heart failure • 2026-10-28 • Phase III Randomized Trial | N = 130 | 88/100 | PMID 42217207 ↗ |
| New Insights on Clazosentan on cerebral vasospasm-related morbidity and all-cause mortality after: What a 221-Participant Study Found Clazosentan significantly reduced the combined incidence of vasospasm-related morbidity and all-cause mortality post-aSAH with no unexpected safety findings. Journal of neurosurgery • 2022-12-01 • Phase III Randomized Trial | N = 221 | 88/100 | PMID 35364589 ↗ |
| Can This Approach Help? Inside the Latest Research on Lipoprotein(a) and coronary atheroma progression rates during long-term In coronary artery disease patients prescribed long-term maximally intensive statin therapy with low on-treatment LDL-C levels, measured Lp(a) levels (predominantly below the 50 mg/dL threshold) do not associate with coronary... Atherosclerosis • 2017-08-15 • Randomized Controlled Trial | Multi-cohort | 82/100 | PMID 28641153 ↗ |
Subarachnoid hemorrhage (SAH) Patient Community & “People Like Me” Threads
Filter Subarachnoid hemorrhage (SAH) community threads and patient logs by age, biological sex, dosage, and treatment duration.